Antisoma plunges as lung-cancer-drug trial halted

Shares of Antisoma skid around 70% on Monday after the British biotech halts a late-stage trial of a lung-cancer drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.